{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:48Z","timestamp":1791273228698,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30370"],"award-info":[{"award-number":["2023JJ30370"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109556","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:19:46Z","timestamp":1785453586000},"page":"109556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer"],"prefix":"10.1016","volume":"219","author":[{"given":"Kai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-7908","authenticated-orcid":false,"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2026.109556_b0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"7689","key":"10.1016\/j.lungcan.2026.109556_b0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109556_b0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109556_b0030","first-page":"153","article-title":"Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109556_b0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109556_b0045","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/JTO.0000000000000644","article-title":"BRAF alterations as therapeutic targets in non-small-cell lung cancer","volume":"10","author":"Nguyen-Ngoc","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109556_b0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2022.05.014","article-title":"Targeting BRAF-mutant non-small cell lung cancer: current status and future directions","volume":"169","author":"Riudavets","year":"2022","journal-title":"Lung Cancer"},{"issue":"26","key":"10.1016\/j.lungcan.2026.109556_b0055","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9839","key":"10.1016\/j.lungcan.2026.109556_b0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.lungcan.2026.109556_b0065","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.lungcan.2026.109556_b0070","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109556_b0080","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","article-title":"MEK inhibitors for the treatment of non-small cell lung cancer","volume":"14","author":"Han","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109556_b0090","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.29825","article-title":"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy","volume":"138","author":"Ross","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2026.109556_b0095","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-23-3981","article-title":"Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets","volume":"30","author":"Chen","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109556_b0100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41416-025-02998-3","article-title":"Unveiling the BRAF fusion structure variations through DNA and RNA sequencing","volume":"132","author":"Yang","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109556_b0105","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109556_b0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.lungcan.2026.109556_b0115","article-title":"Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: a case report and literature review","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109556_b0120","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109556_b0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109556_b0130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","article-title":"Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers","volume":"14","author":"Vojnic","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109556_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103935","article-title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"9","author":"Li","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109556_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.12.001","article-title":"Biology and clinical management of non-V600 BRAF alterations in NSCLC","volume":"21","author":"Ortiz-Cuaran","year":"2026","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109556_b0145","article-title":"BRAF fusion as resistance mechanism to osimertinib in EGFR-mutated NSCLC: a case report and review of literature","volume":"6","author":"Peroni","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109556_b0150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109556_b0155","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109556_b0160","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0165","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","article-title":"Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109556_b0170","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2026.109556_b0175","unstructured":"Shah R. icallSV: A Framework to call Structural Variants from NGS based datasets. 2017. https:\/\/github.com\/rhshah\/iCallSV."},{"key":"10.1016\/j.lungcan.2026.109556_b0180","unstructured":"Shah R. iAnnotateSV: Annotation of structural variants detected from NGS. 2021. https:\/\/github.com\/rhshah\/iAnnotateSV."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109556_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002223","article-title":"Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial","volume":"9","author":"Huang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109556_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer","volume":"582","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109556_b0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Brief. Bioinform."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109556_b0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.lungcan.2026.109556_b0210","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1498053","article-title":"Somatic alteration characteristics of early-onset gastric cancer","volume":"2022","author":"Zhou","year":"2022","journal-title":"J. Oncol."},{"issue":"7463","key":"10.1016\/j.lungcan.2026.109556_b0215","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109556_b0220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16309","article-title":"Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5alpha","volume":"5","author":"Wagner","year":"2016","journal-title":"Elife"},{"issue":"14","key":"10.1016\/j.lungcan.2026.109556_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143337","article-title":"Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies","volume":"14","author":"Koulouris","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109556_b0230","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109556_b0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109556_b0240","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109556_b0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2018.04.012","article-title":"Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer","volume":"121","author":"Nie","year":"2018","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109556_b0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jcb.20255","article-title":"A novel subfamily of zinc finger genes involved in embryonic development","volume":"93","author":"Nakamura","year":"2004","journal-title":"J. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109556_b0255","article-title":"Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt\/mTOR signaling","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109556_b0260","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cam4.847","article-title":"ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer","volume":"5","author":"Baykara","year":"2016","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109556_b0265","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/annonc\/mdy404","article-title":"Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers","volume":"29","author":"Glodzik","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109556_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071930","article-title":"ZNF703 mRNA-targeting antisense oligonucleotide blocks cell proliferation and induces apoptosis in breast cancer cell lines","volume":"15","author":"Udu-Ituma","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109556_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102726","article-title":"The KEAP1-NRF2 pathway: targets for therapy and role in cancer","volume":"63","author":"Adinolfi","year":"2023","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109556_b0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting of NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lungcan.2026.109556_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184079","article-title":"Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers","volume":"13","author":"Lin","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109556_b0290","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3892\/ol.2024.14577","article-title":"Pan\u2011cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy","volume":"28","author":"Cao","year":"2024","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109556_b0295","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1038\/s41598-024-57519-8","article-title":"KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer","volume":"14","author":"Ni","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:27:31Z","timestamp":1791271651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S0169500226006173"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109556","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109556"}}